TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 88 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,478,400

Unlock Full NCT06594991 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06594991 Rescue Dossier →